Results 61 to 70 of about 5,013 (195)

Does a single dose of palonosetron have any role in preventing acute chemotherapy-induced nausea and vomiting in pediatric osteosarcoma patients without dexamethasone? A randomized clinical trial.

Advances in Clinical and Experimental Medicine, 2022
BACKGROUND Chemotherapy-induced nausea and vomiting (CINV) is a troublesome side-effect of chemotherapy in pediatric patients undergoing osteosarcoma treatment.
Zheng Li, Chun Li, Ping Li, Yugang Li, Jin Lai, S. Rastogi   +5 more
semanticscholar   +1 more source

Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach

Internal Medicine Journal, Volume 55, Issue 5, Page 749-759, May 2025.
Abstract Background After pharmaceutical benefits scheme approval of midostaurin for fms‐like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukaemia (AML) in 2018, the Australasian Leukaemia & Lymphoma Group (ALLG) proposed a consensus approach to AML induction with 7+3 chemotherapy (7 days of infusional cytarabine with three doses of anthracycline ...
Aditya Tedjaseputra, Amanda Tey, Anastasios Nalpantidis, George Grigoriadis, Shaun Fleming, Shahla Vilcassim, Pasquale L. Fedele, Michael Sze Yuan Low, Paul Yeh, Michael Gilbertson, Ashwini Bennett, Gareth P. Gregory, Danielle Oh, Donna Gairns, Zane Kaplan, Sanjeev D. Chunilal, Susan Brown, Stephen Opat, Chong C. Chua, Jake Shortt   +19 more
wiley   +1 more source

new UPLC method development and validation for simultaneous estimation of netiputant and palonosetron using bulk and pharmaceutical dosage form using UPLC

International Journal of Health Sciences, 2022
A simple and selective LC method is described for the determination of Netupitant and Palonosetron in tablet dosage forms. Chromatographic separation was achieved on a Inertsil ODS (C18) RP Column (250mm x 4.6 mm.
Shaik Wajid, B. Satyanarayana, Maringanti Rajeev Kumar   +2 more
semanticscholar   +1 more source

CYP2D6 genotype and associated 5‐HT3 receptor antagonist outcomes: A systematic review and meta‐analysis

Clinical and Translational Science, Volume 18, Issue 2, February 2025.
Abstract 5‐hydroxytryptamine‐3 (5‐HT3) receptor antagonists including ondansetron, tropisetron, dolasetron, palonosetron, granisetron, and ramosetron are commonly used to prevent and treat nausea and vomiting. Most of these medications are at least partially metabolized via the highly polymorphic CYP2D6 enzyme, resulting in variations of metabolism ...
Claire Moore, Elizabeth Williams, Roxanne Dyas, Andreas Halman, Tayla Stenta, Dhrita Khatri, David A. Elliott, Peter W Lange, Kelly E. Caudle, Rachel Conyers   +9 more
wiley   +1 more source

A prospective, randomized, double-blind trial to compare body weight-adjusted and fixed doses of palonosetron for preventing postoperative nausea and vomiting in obese female patients.

PLoS ONE, 2020
BackgroundPostoperative nausea and vomiting (PONV) is a common postsurgical complication. Palonosetron is effective for PONV prevention at the usual dose of 75 μg, but the ideal dose for obese patients has not yet been investigated. The aim of this study
Nathalia Gouveia de Araujo Ferreira, Ismar Lima Cavalcanti, Alexandra Rezende Assad, Louis Barrucand, Estêvão Luiz Carvalho Braga, Nubia Verçosa   +5 more
doaj   +1 more source

Bayesian Population Pharmacokinetic Modeling of Ondansetron for Neonatal Opioid Withdrawal Syndrome

Clinical and Translational Science, Volume 18, Issue 2, February 2025.
ABSTRACT Ondansetron is an anti‐emetic 5‐HT3 receptor antagonist being investigated for treating neonatal opioid withdrawal syndrome (NOWS). Sparse PK data were analyzed from a multicenter, double‐blind clinical trial with 98 mother/neonate dyads. Pregnant women with opioid use disorder were randomized to receive either placebo or ondansetron 8 mg ...
Kevin Lam, John T. Mondick, Gary Peltz, Manhong Wu, Walter K. Kraft   +4 more
wiley   +1 more source

Update on the management of chemotherapy-induced nausea and vomiting – focus on palonosetron

Therapeutics and Clinical Risk Management, 2015
Michelle Zhou, Marko Popovic, Mark Pasetka, Natalie Pulenzas, Soha Ahrari, Edward Chow, Carlo DeAngelis Department of Pharmacy, Odette Cancer Center, Sunnybrook Health Sciences Center, University of Toronto, Toronto, ON, Canada Purpose: Nausea and
Zhou M, Popovic M, Pasetka M, Pulenzas N, Ahrari S, Chow E, DeAngelis C   +6 more
doaj  

Comparison of ondansetron, tropisetron, and palonosetron for the prevention of postoperative nausea and vomiting after middle ear surgery

Current Therapeutic Research, 2019
: Background: Postoperative nausea and vomiting (PONV) are 2 of the most frequent adverse effects of anesthesia. PONV prolongs hospital stays and also delays the recovery of patients.
Ahmet Aydin, MD, Mustafa Kaçmaz, MD, Adem Boyaci, MD   +2 more
doaj   +1 more source

Comparison of Antiemetic Effectiveness of Palonosetron Versus Ondansetron in Patients on Cancer Chemotherapy: A Prospective Observational Study in South Indians [PDF]

Journal of Clinical and Diagnostic Research, 2017
Introduction: Chemotherapy Induced Nausea and Vomiting (CINV) is the most distressing side effect of cancer chemotherapy. It can seriously produce an impact on patient's quality of life.
Abdul Aslam Parathoduvil, Asha Sisupalan, Padanayil Lekshmikutty Rema   +2 more
doaj   +1 more source

Data‐driven discovery of associations between prescribed drugs and dementia risk: A systematic review

Alzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 11, Issue 1, January-March 2025.
Abstract Recent clinical trials on slowing dementia progression have led to renewed focus on finding safer, more effective treatments. One approach to identify plausible candidates is to assess whether existing medications for other conditions may affect dementia risk. We conducted a systematic review to identify studies adopting a data‐driven approach
Benjamin R. Underwood, Ilianna Lourida, Jessica Gong, Stefano Tamburin, Eugene Yee Hing Tang, Emad Sidhom, Xin You Tai, Matthew J. Betts, Janice M. Ranson, Margarita Zachariou, Olajide E. Olaleye, Saswati Das, Neil P. Oxtoby, Shanquan Chen, David J. Llewellyn, for the Deep Dementia Phenotyping (DEMON) Network   +15 more
wiley   +1 more source